Clinical Trial Update: Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo. [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the effectiveness and safety of ramipril alone, telmisartan alone, and the ramipril-telmisartan combination in high-risk cardiovascular …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases

Drugs mentioned

• Ramipril (ramipril)
• Telmisartan (Telmisartan)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Cardiovascular Diseases | Phase 4 | Status: COMPLETED | Results posted: 2009-08-25